{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:35:21Z","timestamp":1783632921171,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-024-02382-7","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T14:02:26Z","timestamp":1714658546000},"page":"2835-2842","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Targeted therapy in  BRAF\u00a0mutated aggressive papillary craniopharyngioma: a case report and overview of the literature"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7810-8247","authenticated-orcid":false,"given":"M.","family":"Losa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Mazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Pedone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Nocera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Liscia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Reni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Mortini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,2]]},"reference":[{"issue":"4","key":"2382_CR1","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1210\/er.2006-0002","volume":"27","author":"N Karavitaki","year":"2006","unstructured":"Karavitaki N, Cudlip S, Adams CB, Wass JA (2006) Craniopharyngiomas. Endocr Rev 27(4):371\u2013397. https:\/\/doi.org\/10.1210\/er.2006-0002","journal-title":"Endocr Rev"},{"issue":"5","key":"2382_CR2","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.3171\/2010.11.JNS10670","volume":"114","author":"P Mortini","year":"2011","unstructured":"Mortini P, Losa M, Pozzobon G, Barzaghi R, Riva M, Acerno S, Angius D, Weber G, Chiumello G, Giovanelli M (2011) Neurosurgical treatment of craniopharyngioma in adults and children: early and long-term results in a large case series. J Neurosurg 114(5):1350\u20131359. https:\/\/doi.org\/10.3171\/2010.11.JNS10670","journal-title":"J Neurosurg"},{"issue":"4","key":"2382_CR3","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1002\/1097-0142(197604)37","volume":"37","author":"CK Petito","year":"1976","unstructured":"Petito CK, De Girolami U, Earle K (1976) Craniopharyngiomas. A clinical and pathological review. Cancer 37(4):1944\u20131952. https:\/\/doi.org\/10.1002\/1097-0142(197604)37. (4<1944::aid-cncr2820370446>3.0.co;2-#)","journal-title":"Cancer"},{"issue":"7","key":"2382_CR4","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/hed.21771","volume":"34","author":"JC Fernandez-Miranda","year":"2012","unstructured":"Fernandez-Miranda JC, Gardner PA, Snyderman CH, Devaney KO, Strojan P, Suarez C, Genden EM, Rinaldo A, Ferlito A (2012) Craniopharyngioma: a pathologic, clinical, and surgical review. Head Neck 34(7):1036\u20131044. https:\/\/doi.org\/10.1002\/hed.21771","journal-title":"Head Neck"},{"issue":"6","key":"2382_CR5","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1227\/00006123-199412000-00001","volume":"35","author":"HL Weiner","year":"1994","unstructured":"Weiner HL, Wisoff JH, Rosenberg ME, Kupersmith MJ, Cohen H, Zagzag D, Shiminski-Maher T, Flamm ES, Epstein FJ, Miller DC (1994) Craniopharyngiomas: a clinicopathological analysis of factors predictive of recurrence and functional outcome. Neurosurgery 35(6):1001\u20131010. https:\/\/doi.org\/10.1227\/00006123-199412000-00001. (discussion 1010-1011)","journal-title":"Neurosurgery"},{"issue":"3","key":"2382_CR6","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.critrevonc.2013.07.013","volume":"88","author":"P Mortini","year":"2013","unstructured":"Mortini P, Gagliardi F, Boari N, Losa M (2013) Surgical strategies and modern therapeutic options in the treatment of craniopharyngiomas. Crit Rev Oncol Hematol 88(3):514\u2013529. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.07.013","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"2382_CR7","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1210\/jcem.83.11.5240","volume":"83","author":"B B\u00fclow","year":"1998","unstructured":"B\u00fclow B, Attewell R, Hagmar L, Malmstr\u00f6m P, Nordstr\u00f6m CH, Erfurth EM (1998) Postoperative prognosis in craniopharyngioma with respect to cardiovascular mortality, survival, and tumor recurrence. J Clin Endocrinol Metab 83(11):3897\u20133904. https:\/\/doi.org\/10.1210\/jcem.83.11.5240","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2382_CR8","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s11102-018-0903-5","volume":"21","author":"M Losa","year":"2018","unstructured":"Losa M, Pieri V, Bailo M, Gagliardi F, Barzaghi LR, Gioia L, Del Vecchio A, Bolognesi A, Mortini P (2018) Single fraction and multisession Gamma Knife radiosurgery for craniopharyngioma. Pituitary 21(5):499\u2013506. https:\/\/doi.org\/10.1007\/s11102-018-0903-5","journal-title":"Pituitary"},{"issue":"2","key":"2382_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/ng.2868","volume":"46","author":"PK Brastianos","year":"2014","unstructured":"Brastianos PK, Taylor-Weiner A, Manley PE, Jones RT, Dias-Santagata D, Thorner AR, Lawrence MS, Rodriguez FJ, Bernardo LA, Schubert L, Sunkavalli A, Shillingford N, Calicchio ML, Lidov HG, Taha H, Martinez-Lage M, Santi M, Storm PB, Lee JY, Palmer JN, Adappa ND, Scott RM, Dunn IF, Laws ER Jr, Stewart C, Ligon KL, Hoang MP, Van Hummelen P, Hahn WC, Louis DN, Resnick AC, Kieran MW, Getz G, Santagata S (2014) Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet 46(2):161\u2013165. https:\/\/doi.org\/10.1038\/ng.2868","journal-title":"Nat Genet"},{"issue":"12","key":"2382_CR10","doi-asserted-by":"publisher","first-page":"5751","DOI":"10.1210\/jc.2019-01299","volume":"104","author":"KI Alexandraki","year":"2019","unstructured":"Alexandraki KI, Kaltsas GA, Karavitaki N, Grossman AB (2019) The medical therapy of craniopharyngiomas: the way ahead. J Clin Endocrinol Metab 104(12):5751\u20135764. https:\/\/doi.org\/10.1210\/jc.2019-01299","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2382_CR11","doi-asserted-by":"publisher","first-page":"djv310","DOI":"10.1093\/jnci\/djv310","volume":"108","author":"PK Brastianos","year":"2015","unstructured":"Brastianos PK, Shankar GM, Gill CM, Taylor-Weiner A, Nayyar N, Panka DJ, Sullivan RJ, Frederick DT, Abedalthagafi M, Jones PS, Dunn IF, Nahed BV, Romero JM, Louis DN, Getz G, Cahill DP, Santagata S, Curry WT Jr, Barker FG 2nd (2015) Dramatic response of BRAF V600E mutant papillary craniopharyngioma to targeted therapy. J Natl Cancer Inst 108(2):djv310. https:\/\/doi.org\/10.1093\/jnci\/djv310","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"2382_CR12","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s11102-015-0663-4","volume":"19","author":"SJ Aylwin","year":"2016","unstructured":"Aylwin SJ, Bodi I, Beaney R (2016) Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor. Pituitary 19(5):544\u2013546. https:\/\/doi.org\/10.1007\/s11102-015-0663-4","journal-title":"Pituitary"},{"issue":"2","key":"2382_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2217\/cns-2016-0034","volume":"6","author":"A Roque","year":"2017","unstructured":"Roque A, Odia Y (2017) BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors. CNS Oncol 6(2):95\u201399. https:\/\/doi.org\/10.2217\/cns-2016-0034","journal-title":"CNS Oncol"},{"issue":"11","key":"2382_CR14","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1007\/s00701-017-3311-0","volume":"159","author":"E Rostami","year":"2017","unstructured":"Rostami E, Witt Nystr\u00f6m P, Libard S, Wikstr\u00f6m J, Casar-Borota O, Gudjonsson O (2017) Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant -targeted therapy. Acta Neurochir (Wien) 159(11):2217\u20132221. https:\/\/doi.org\/10.1007\/s00701-017-3311-0","journal-title":"Acta Neurochir (Wien)"},{"key":"2382_CR15","doi-asserted-by":"publisher","DOI":"10.3171\/2017.11.JNS172373","author":"BT Himes","year":"2018","unstructured":"Himes BT, Ruff MW, Van Gompel JJ, Park SS, Galanis E, Kaufmann TJ, Uhm JH (2018) Recurrent papillary craniopharyngioma withBRAF\u00a0V600E mutation treated with dabrafenib: case report. J Neurosurg. https:\/\/doi.org\/10.3171\/2017.11.JNS172373","journal-title":"J Neurosurg"},{"issue":"17","key":"2382_CR16","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1002\/cncr.32197","volume":"125","author":"TA Juratli","year":"2019","unstructured":"Juratli TA, Jones PS, Wang N, Subramanian M, Aylwin SJB, Odia Y, Rostami E, Gudjonsson O, Shaw BL, Cahill DP, Galanis E, Barker FG 2nd, Santagata S, Brastianos PK (2019) Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations. Cancer 125(17):2910\u20132914. https:\/\/doi.org\/10.1002\/cncr.32197","journal-title":"Cancer"},{"issue":"57","key":"2382_CR17","doi-asserted-by":"publisher","first-page":"6038","DOI":"10.18632\/oncotarget.27203","volume":"10","author":"M Rao","year":"2019","unstructured":"Rao M, Bhattacharjee M, Shepard S, Hsu S (2019) Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report. Oncotarget 10(57):6038\u20136042. https:\/\/doi.org\/10.18632\/oncotarget.27203","journal-title":"Oncotarget"},{"issue":"6","key":"2382_CR18","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.3171\/2019.8.JNS19643","volume":"144","author":"A Bernstein","year":"2019","unstructured":"Bernstein A, Mrowczynski OD, Greene A, Ryan S, Chung C, Zacharia BE, Glantz M (2019) Dual BRAF\/MEK therapy in BRAF V600E-mutated primary brain tumors: a case series showing dramatic clinical and radiographic responses and a reduction in cutaneous toxicity. J Neurosurg 144(6):1704\u20131709. https:\/\/doi.org\/10.3171\/2019.8.JNS19643","journal-title":"J Neurosurg"},{"issue":"1","key":"2382_CR19","doi-asserted-by":"publisher","first-page":"vdaa141","DOI":"10.1093\/noajnl\/vdaa141","volume":"2","author":"AL Di Stefano","year":"2020","unstructured":"Di Stefano AL, Guyon D, Sejean K, Feuvret L, Villa C, Berzero G, Desforges Bullet V, Halimi E, Boulin A, Baussart B, Gaillard S (2020) Medical debulking with BRAF\/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma. Neurooncol Adv 2(1):vdaa141. https:\/\/doi.org\/10.1093\/noajnl\/vdaa141","journal-title":"Neurooncol Adv"},{"issue":"12","key":"2382_CR20","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.6004\/jnccn.2020.7624","volume":"18","author":"K Khaddour","year":"2020","unstructured":"Khaddour K, Chicoine MR, Huang J, Dahiya S, Ansstas G (2020) Successful use of BRAF\/MEK inhibitors as a neoadjuvant approach in the definitive treatment of papillary craniopharyngioma. J Natl Compr Canc Netw 18(12):1590\u20131595. https:\/\/doi.org\/10.6004\/jnccn.2020.7624","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"2382_CR21","doi-asserted-by":"publisher","first-page":"bvab043","DOI":"10.1210\/jendso\/bvab043","volume":"5","author":"CL Chik","year":"2021","unstructured":"Chik CL, van Landeghem FKH, Easaw JC, Mehta V (2021) Aggressive childhood-onset papillary craniopharyngioma managed with Vemurafenib, a BRAF inhibitor. J Endocr Soc 5(5):bvab043. https:\/\/doi.org\/10.1210\/jendso\/bvab043","journal-title":"J Endocr Soc"},{"key":"2382_CR22","doi-asserted-by":"publisher","first-page":"652005","DOI":"10.3389\/fmed.2021.652005","volume":"8","author":"M Fasano","year":"2022","unstructured":"Fasano M, Della Corte CM, Caterino M, Pirozzi M, Rauso R, Troiani T, Martini G, Napolitano S, Morgillo F, Ciardiello F (2022) Dramatic therapeutic response to dabrafenib plus trametinib in BRAF V600E mutated papillary craniopharyngiomas: a case report and literature review. Front Med (Lausanne) 8:652005. https:\/\/doi.org\/10.3389\/fmed.2021.652005","journal-title":"Front Med (Lausanne)"},{"key":"2382_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13600","author":"PE Nussbaum","year":"2022","unstructured":"Nussbaum PE, Nussbaum LA, Torok CM, Patel PD, Yesavage TA, Nussbaum ES (2022) Case report and literature review of BRAF-V600 inhibitors for treatment of papillary craniopharyngiomas: a potential treatment paradigm shift. J Clin Pharm Ther. https:\/\/doi.org\/10.1111\/jcpt.13600","journal-title":"J Clin Pharm Ther"},{"key":"2382_CR24","doi-asserted-by":"publisher","first-page":"882381","DOI":"10.3389\/fendo.2022.882381","volume":"13","author":"F Calvanese","year":"2022","unstructured":"Calvanese F, Jacquesson T, Manet R, Vasiljevic A, Lasolle H, Ducray F, Raverot G, Jouanneau E (2022) Neoadjuvant B-RAF and MEK inhibitor targeted therapy for adult papillary craniopharyngiomas: a new treatment paradigm. Front Endocrinol (Lausanne) 13:882381. https:\/\/doi.org\/10.3389\/fendo.2022.882381","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2382_CR25","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa2213329","volume":"389","author":"PK Brastianos","year":"2023","unstructured":"Brastianos PK, Twohy E, Geyer S, Gerstner ER, Kaufmann TJ, Tabrizi S, Kabat B, Thierauf J, Ruff MW, Bota DA, Reardon DA, Cohen AL, De La Fuente MI, Lesser GJ, Campian J, Agarwalla PK, Kumthekar P, Mann B, Vora S, Knopp M, Iafrate AJ, Curry WT Jr, Cahill DP, Shih HA, Brown PD, Santagata S, Barker FG 2nd, Galanis E (2023) BRAF-MEK inhibition in newly diagnosed papillary craniopharyngiomas. N Engl J Med 389(2):118\u2013126. https:\/\/doi.org\/10.1056\/NEJMoa2213329","journal-title":"N Engl J Med"},{"issue":"2","key":"2382_CR26","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1177\/1758834014566428","volume":"7","author":"SJ Welsh","year":"2015","unstructured":"Welsh SJ, Corrie PG (2015) Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther Adv Med Oncol 7(2):122\u2013136. https:\/\/doi.org\/10.1177\/1758834014566428","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"2382_CR27","doi-asserted-by":"publisher","first-page":"e000491","DOI":"10.1136\/esmoopen-2019-000491","volume":"4","author":"L Heinzerling","year":"2019","unstructured":"Heinzerling L, Eigentler TK, Fluck M, Hassel JC, Heller-Schenck D, Leipe J, Pauschinger M, Vogel A, Zimmer L, Gutzmer R (2019) Tolerability of BRAF\/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open 4(3):e000491. https:\/\/doi.org\/10.1136\/esmoopen-2019-000491","journal-title":"ESMO Open"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02382-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-024-02382-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02382-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T10:04:29Z","timestamp":1728900269000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-024-02382-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":27,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["2382"],"URL":"https:\/\/doi.org\/10.1007\/s40618-024-02382-7","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,2]]},"assertion":[{"value":"14 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest. The authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol complies with the 1964 Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human participants and animals"}},{"value":"A signed informed consent for all the therapeutic procedures was obtained from the patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}